Drug registration reform policies have been introduced frequently, and R&D pharmaceutical companies have ushered in the spring. In the face of stricter drug quality supervision, high-quality listed companies generally have strong quality management systems, or will benefit from industry norms as a whole.

Improving the standard of drug evaluation will delay the progress of drug approval, and some clinical data of drugs will be ordered to supplement, or even require re-clinical trials. In the short term, it will affect future profits and bring certain pressure to enterprises. But in the long run, after the optimization of the evaluation system, the backlog of accepted orders will be reduced, and the progress of drug queuing approval will be greatly accelerated, which is undoubtedly a big plus for enterprises.

Having said that, the market is not very good now. If you don't worry about the risk, you can choose a fixed investment, which is less risky. If you don't want to, you can choose to wait and see, and then buy when the market improves. I hope my answer can give you more help, and I hope it will be adopted!